Biotheus
Latest round
- Series B
Last raised
- Mar 2021
Total raised
- $100M
Investors
- 11
About Biotheus
Established in 2018, and based in Zhuhai, China, Biotheus Inc. specializes in biotechnology and biologic therapeutics. The company was founded by Andy Tsun, Joanne Sun, and Xiaolin Liu, who is also the CEO. Its headquarters is located in Zhuhai, China. Over its operational years, Biotheus has completed five deals. Biotheus specializes in the development and provision of innovative biotechnology solutions aimed at enhancing human health and wellness. The company's core offerings include a range of biologic therapeutics designed to address various medical conditions through advanced biological processes. These products are targeted primarily at healthcare providers, pharmaceutical companies, and research institutions, enabling them to improve patient outcomes through more effective treatment options. Biotheus has positioned its products in international markets including North America, Europe, and parts of Asia, aiming to meet the growing demand for advanced medical solutions. The revenue model of Biotheus is primarily based on partnerships with healthcare organizations and direct sales of its proprietary therapeutic products. Transactions typically occur through long-term agreements with pharmaceutical companies that utilize Biotheus's biologics in their treatment protocols, facilitating a steady income flow. The company employs a B2B structure, where it collaborates directly with healthcare providers and research institutions to distribute its products. Specific pricing plans for their flagship therapeutics are established based on the value they provide in clinical outcomes, ensuring that clients receive high-quality solutions at competitive rates. This model effectively supports Biotheus's goal of expanding its market presence while delivering significant health benefits to a broad range of end-users. In light of the acquisition by BioNTech, Biotheus Inc. plans to advance its immuno-oncology pipeline and expand its research and development, as well as its clinical trial capabilities, particularly in China.00 mn, will be strategically utilized to support the development of new products and enhance the company's operational capacities. This includes launching new therapeutic solutions aimed at addressing unmet medical needs and entering into additional markets within North America and Europe by the end of 2025.00 mn contingent upon achieving certain milestones underscores the commitment to continued growth and innovation.
Who invested in Biotheus
11 investors across 2 rounds
See all investors in Biotheus
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Biotheus
Who invested in Biotheus?
Biotheus has 11 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Biotheus raised?
Biotheus has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Biotheus last raise money?
Biotheus's most recent round on record is a Series B, in Mar 2021.
What does Biotheus do?
Established in 2018, and based in Zhuhai, China, Biotheus Inc.
Where is Biotheus headquartered?
Biotheus is headquartered in Zhuhai, China.
Which VCs invest in companies like Biotheus?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Biotheus's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Biotheus? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.